Cabaletta Bio Reports Breakthrough Results in Autoimmune Disease Trials
PHILADELPHIA, PA — Cabaletta Bio, Inc. (Nasdaq: CABA) unveiled promising clinical data from its RESET-Myositis™, RESET-SSc™, and RESET-SLE™ trials evaluating rese-cel (resecabtagene autoleucel), reinforcing its potential to deliver long-lasting, drug-free …
Cabaletta Bio Reports Breakthrough Results in Autoimmune Disease Trials Read More